North America Next-generation Sequencing Market

The North America next-generation sequencing (NGS) market is anticipated to reach USD 11.63 billion by 2030 from USD 6.15 billion in 2025, at a CAGR of 13.6%. Major growth drivers of the North America NGS market are the rising funding and investment in genomics and the rapidly expanding pipeline of NGS-based research and clinical applications.

To know about the assumptions considered for the study download the pdf brochure

The North America market for next-generation sequencing is consolidated. Prominent players in the North America next-generation sequencing market are Illumina, Inc. (US), Thermo Fisher Scientific Inc. (US), Danaher Corporation (US), and BD (US), among others.

In October 2024, Illumina launched the MiSeq i100 sequencing system, featuring high benchtop speed and simplicity, to advance NGS for laboratories. In July 2024, Illumina acquired Fluent BioSciences, a developer of an emerging and highly differentiated single-cell technology. This will help advance multi-omics growth strategies.

Illumina, Inc. is among the leading companies in the North America next-generation sequencing market. It is a molecular diagnostics company that designs, manufactures, and commercializes integrated systems to analyze genetic variation and biological function. The company’s portfolio spans integrated instruments, consumables, and analysis software aimed at simplifying genetic analysis, with sequencing products offered through its instruments & consumables segment and sequencing services provided under its service and other revenue segment. Continuous R&D investment enables Illumina to advance sequencing technology, enhance accuracy and throughput, and open new applications.

Thermo Fisher Scientific Inc. is one of the leaders in the North America next-generation sequencing market. The company benefits from a large salesforce and an extensive global reseller and distribution network. Over the past three years, it has concentrated on product innovation, introducing multiple new solutions to reinforce its competitive position in NGS. Key launches include the Ion AmpliSeq SARS-CoV-2 Research Panel, Ion Torrent Oncomine Myeloid MRD Assays (RUO), Ion Torrent Oncomine immune repertoire assays, and the Ion Torrent Genexus System. In May 2024, Thermo Fisher Scientific also introduced the Applied Biosystems Axiom BloodGenomix Array and Software to enable more precise blood genotyping in hematologic disorders.

Agilent Technologies, Inc. delivers NGS offerings through its Diagnostics and Genomics business segment, which spans five key areas: Genomics, Nucleic Acid Contract Manufacturing and R&D, Pathology, Companion Diagnostics, and Reagent Partnerships. The company invests heavily in R&D to enhance its portfolio and support a robust pipeline of products for the expanding NGS market. It also pursues inorganic growth through agreements and acquisitions to maintain its competitive edge. For example, in August 2023, Agilent entered a partnership with Element Biosciences to jointly market Agilent’s and Element’s products in the US.

Market Ranking

The North America NGS market is competitive, with several global players capturing a significant share of regional revenues. Illumina maintains a leading position with a broad portfolio of sequencing platforms, reagents, and informatics solutions that serve high-throughput research, clinical diagnostics, and population genomics programs, supported by a substantial installed base and a robust service network. Thermo Fisher Scientific is another key player, offering integrated NGS solutions built around its Ion Torrent technology, including instruments, library preparation kits, and data analysis tools optimized for targeted applications in oncology, infectious diseases, and inherited disorders. Agilent Technologies and other suppliers are adding to the ecosystem through specialized offerings in library preparation, target enrichment, QC, and automation-ready workflows, enabling flexible and high-performance sequencing across research and clinical setups. Additionally, apart from these market players, the market is fragmented with regional sequencing product and service providers, sample preparation-focused players, and bioinformatics firms that address specific unmet needs such as custom panels, RNA-seq, and integrated clinical reporting. Recent trends highlight strong momentum toward end-to-end workflows, automation, and cloud-based analytics tools, as suppliers compete on ease of use, turnaround time, and total cost of ownership to support the expanding NGS adoption across North America's healthcare and biopharmaceutical end users.

Related Reports:

North America Next-generation Sequencing Market by Product Type (Consumables, Platforms, Bioinformatics), Technology (SBS, Nanopore), Workflow (Sequencing, Data Analysis), Service, Application (Drug Discovery, Diagnostic, Agriculture) - Forecast to 2030

Contact:
Mr. Rohan Salgarkar
MarketsandMarkets™ INC.
1615 South Congress Ave.
Suite 103, Delray Beach, FL 33445
USA : 1-888-600-6441
sales@marketsandmarkets.com